Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients

Cancer Science

Volumn 104, Issue 1, 2013, Pages 124-129

  Kameshima, Hidekazu ^a   Tsuruma, Tetsuhiro ^a   Kutomi, Goro ^a   Shima, Hiroaki ^a   Iwayama, Yuji ^a   Kimura, Yasutoshi ^a   Imamura, Masahumi ^a   Torigoe, Toshihiko ^a   Takahashi, Akari ^a   Hirohashi, Yoshihiko ^a   Tamura, Yasuaki ^a   Tsukahara, Tomohide ^a   Kanaseki, Takayuki ^a   Sato, Noriyuki ^a   Hirata, Koichi ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; RECOMBINANT ALPHA INTERFERON; SURVIVIN 2B8088; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; VACCINATION;

AGED; AGED, 80 AND OVER; CANCER VACCINES; COLONIC NEOPLASMS; FEMALE; HLA-A24 ANTIGEN; HUMANS; IMMUNOTHERAPY; INHIBITOR OF APOPTOSIS PROTEINS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; VACCINES, SUBUNIT;

EID: 84872277773     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12046     Document Type: Article

References (29)

1. Hirohashi Y, Torigoe T, Inoda S et al. The functioning antigens; beyond just as the immunologic targets. Cancer Sci 2009; 100: 798-806.
2. Sato N, Hirohashi Y, Tsukahara T et al. Molecular pathologic approaches to human tumor immunology. Pathol Int 2009; 59: 205-17.
3. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nature Med 2004; 10: 909-15.
4. Tsukahara T, Torigoe T, Tamura Y, Kawaguchi S, Wada T, Sato N. Antigenic peptide vaccination: provoking immune response and clinical benefit for cancer. Curr Immunol Rev 2008; 4: 235-41.
5. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999; 10: 281-7.
6. Andersen MH, Becker JC, Straten P. Regulators of apoptosis: suitable targets for immune therapy of cancer. Nat Rev Drug Discov 2005; 4: 399-409.
7. Van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
8. Kameshima H, Tsuruma T, Torigoe T et al. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Sci 2011; 102: 1181-7.
9. Tsuruma T, Hata F, Torigoe T et al. PhaseI clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004; 2: 19-29.
10. Tsuruma T, Iwayama Y, Ohmura T et al. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J Transl Med 2008; 6: 24-35.
11. Kawaguchi S, Wada T, Ida K et al. Phase Ivaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J Transl Med 2005; 3: 1-9.
12. Honma I, Kitamura H, Torigoe H et al. Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer. Cancer Immunol Immunother 2009; 58: 1801-7.
13. Torigoe T, Asanuma H, Nakazawa E et al. Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: unusually high frequency of down-regulation in breast cancer tissues. Pathol Int 2012; 62: 303-8.
14. Coulie PG, Karanikas V, Lurquin C. Cytolytic T-cell response of cancer patients vaccinated with a MAGE antigen. Immunol Rev 2002; 188: 33-42.
15. Nagaraj S, Pisarev V, Kinarsky L et al. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors. J Immunother 2007; 30: 169-79.
16. Hirohashi Y, Torigoe T, Maeda A et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 2002; 8: 1731-9.
17. Idenoue S, Hirohashi Y, Torigoe T et al. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res 2005; 11: 1474-82.
18. + T cells stimulated by virus-induced type I interferon. Nat Immunol 2003; 4: 1009-15.
19. + T regulatory 1 cells. J Immunol 2005; 174: 99-109.
20. + T cells and monocyte/dendritic cell precursors. Cancer Res 2006; 66: 4943-51.
21. Gigante M, Mandic M, Wesa AK et al. Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients. J Immunother 2008; 31: 254-62.
22. Schwaab T, Schwarzer A, Wolf B et al. Clinical and immunologic effect of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukim (interleukin 2) and IFN-α2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res 2009; 15: 4986-92.
23. Trepiakas R, Pedersen AE, Met O, Svane IM. Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function. Vaccine 2009; 27: 2213-9.
24. Shimizu K, Kurosawa Y, Taniguchi M, Steinman RM, Fujii S. Cross-presentation of glycolipid from tumor cells loaded with α-galactsylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J Exp Med 2007; 204: 2641-53.
25. + T-cell memory and prime-boost response after dendritic-cell vaccination. Nature Med 2005; 11: 748-56.
26. Spadaro F, Lapenta C, Donati S et al. IFN-α enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood 2012; 119: 1407-17.
27. Truong P, Heydari S, Garidou L, McGavern DB. Persistent viral infection elevates central nervous system MHC class I through chronic production of interferons. J Immunol. 2009; 183: 3895-905.
28. Garrido F, Cabrera T, Aptsiauri N. Hard and soft lesions underlying the HLA class I alterations in cancer cells; implications for immunotherapy. Int J Cancer 2010; 127: 249-56.
29. Khallouf H, Marten A, Serba S et al. 5-Fluorouracil and interferon-α immunotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2S ligands and MHC class I. J Immunother 2012; 35: 245-53.